Drug delivery strategies for the treatment of malignant gliomas.
about
The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeuticsNovel strategies in glioblastoma surgery aim at safe, supra-maximum resection in conjunction with local therapiesEvolving Drug Delivery Strategies to Overcome the Blood Brain Barrier.Drug delivery strategies to enhance the permeability of the blood-brain barrier for treatment of gliomaSpherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastomaExtracellular diffusion quantified by magnetic resonance imaging during rat C6 glioma cell progressionRedox-responsive magnetic nanoparticle for targeted convection-enhanced delivery of O6-benzylguanine to brain tumorsIntratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion.Novel central nervous system drug delivery systems.miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma.Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma.Development and evaluation of sustained-release etoposide-loaded poly(ε-caprolactone) implants.Anti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapyMultimodal imaging enables early detection and characterization of changes in tumor permeability of brain metastases.Interleukins in glioblastoma pathophysiology: implications for therapy.Targeted delivery of nano-therapeutics for major disorders of the central nervous system.Therapeutic cell carriers: a potential road to cure glioma.Management of diffuse intrinsic pontine glioma in children: current and future strategies for improving prognosis.Intra-individual comparison of different gadolinium-based contrast agents in the quantitative evaluation of C6 glioma with dynamic contrast-enhanced magnetic resonance imaging.A conformal hydrogel nanocomposite for local delivery of paclitaxel.Neural stem cells, the subventricular zone and radiotherapy: implications for treating glioblastoma.Disruption of prion protein-HOP engagement impairs glioblastoma growth and cognitive decline and improves overall survival.MRI contrast agent for targeting glioma: interleukin-13 labeled liposome encapsulating gadolinium-DTPA.Convection-enhanced delivery for targeted delivery of antiglioma agents: the translational experience.Platelet activating factor induces transient blood-brain barrier opening to facilitate edaravone penetration into the brain.EMP-induced BBB-disruption enhances drug delivery to glioma and increases treatment efficacy in rats.L-Carnitine-conjugated nanoparticles to promote permeation across blood-brain barrier and to target glioma cells for drug delivery via the novel organic cation/carnitine transporter OCTN2.Transporter-Guided Delivery of Nanoparticles to Improve Drug Permeation across Cellular Barriers and Drug Exposure to Selective Cell Types.
P2860
Q26795601-D749C128-C7F7-44E9-9320-85D2B577235CQ27023618-C28D2AF7-131E-4A7E-9FD3-61F7A4A96EA5Q28082016-8CCE3560-1449-42E0-A520-3AF6C9E2F0C6Q30413487-43742463-2A97-4047-B26C-17A40134B38EQ30577878-5D35E2E5-7A73-46DC-AA76-DF7C99E129C9Q33868274-4FCC8CDD-7A06-4FC7-8FAE-27446708D590Q34419939-3655324E-1EB9-46D0-B464-923A6F4D550FQ34775318-424FE912-B5D9-4499-A042-E517D19A8145Q35064473-4EE6F596-F032-449F-9877-7B818F52CC6CQ35293772-C492FA3E-B523-4EB3-9C93-D3A470099415Q36297929-4400C8E4-472E-44DA-9C9F-8E9288316CE4Q36882127-BB759F3B-6B0F-41A4-A44D-0C4261D2186BQ37301832-19B45F85-3226-4B6B-A2B2-0C1DC2022D22Q37579928-FBF6247C-33FD-421D-BE8F-EAA1E016FE06Q38051761-BE4BA618-DE27-4782-AC2D-004880137C22Q38116765-A54A5450-E333-4B94-A18E-0BE8E37A6BA1Q38213836-C67E1D7E-7D1A-47C4-9D7D-B4A54DADF874Q38273428-78EABFA9-F986-454C-B878-47901C584DF9Q38721755-FE452C50-ED3F-4E94-90D3-8066CA429B98Q38802479-3A161E93-10A4-447B-BC8B-7A17C5FE800EQ38815922-7F75C4CE-5FF0-4267-B9C1-F8AAF7EA3F6FQ38963334-2814972D-7B8E-44CD-9A41-C5BC65E2ECDDQ40016483-D914D3AF-6909-46F9-8C41-D023E491CA09Q41670963-BC490B43-A890-4472-B18B-528DA3904764Q44610359-3835A6DB-5854-4B6B-9FBC-641F8E09EC1DQ47653500-C39F94D7-5B7F-4632-950B-9A25E4712F55Q48035129-DB246DDA-A421-438C-B7C0-12CDA4F35C81Q49472868-08125230-EBFF-486D-A4B0-6191BB003552
P2860
Drug delivery strategies for the treatment of malignant gliomas.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Drug delivery strategies for the treatment of malignant gliomas.
@ast
Drug delivery strategies for the treatment of malignant gliomas.
@en
Drug delivery strategies for the treatment of malignant gliomas.
@nl
type
label
Drug delivery strategies for the treatment of malignant gliomas.
@ast
Drug delivery strategies for the treatment of malignant gliomas.
@en
Drug delivery strategies for the treatment of malignant gliomas.
@nl
prefLabel
Drug delivery strategies for the treatment of malignant gliomas.
@ast
Drug delivery strategies for the treatment of malignant gliomas.
@en
Drug delivery strategies for the treatment of malignant gliomas.
@nl
P2093
P1476
Drug delivery strategies for the treatment of malignant gliomas.
@en
P2093
Alf Lamprecht
Daniela Allhenn
Maryam Alsadat Shetab Boushehri
P304
P356
10.1016/J.IJPHARM.2012.06.025
P407
P577
2012-06-19T00:00:00Z